Press Releases
Samsung Biologics opens New Jersey office to strengthen global network
Samsung Biologics recently opened a regional office in New Jersey to extend its client support in the U.S. and beyond. Along with the company’s R&D Center in San Francisco, Samsung Biologics expects the new office to streamline communication and enable the company to work in closer proximity to clients based in the U.S. and Europe.
|
Kyung-Sik Choi (Right), President and CEO of Samsung Electronics North America, attends the opening ceremony to welcome Samsung Biologics employees to New Jersey |
“The opening of our new sales office is a significant moment for us as we further seek to strengthen our global relationships with both existing and new clients in the U.S. and Europe,” said John Rim, President and CEO of Samsung Biologics, during the opening ceremony. “This reflects our dedication to continuously anticipate and meet the needs of our clients, wherever they are located.”
Samsung Biologics says the increased U.S. presence will enable the company to provide support for clients with even greater agility and flexibility, as well as engage the broader biotech industry more than ever.
“Our employees lead with a client satisfaction mindset, and thanks to their commitment and drive, this location will enable us to develop stronger relationships and better tailor solutions for our clients,” said Kevin Sharp, Vice President and Head of Samsung Biologics America Sales.
|
Samsung Biologics’ New Jersey office receives warm welcome from the Samsung Electronics North America team |
In addition to its U.S. footprint, the company will expand its headquarters in Korea with the construction of a fifth plant as part of its second Bio Campus. In response to increased global demand for biopharmaceutical products, Samsung Biologics will invest KRW 7.5 trillion to fulfill the company’s strategic commitment to continuous capacity expansion at its Songdo headquarters.
The company also plans to diversify its portfolio to include next generation biomedicines, including bispecific antibodies and antibody drug conjugates. Samsung Biologics will continue to provide customers with even greater innovation and services that will increase speed to market and boost patient access to live-saving treatments.
Related contents
Press Release Samsung Biologics announces construction of Plant 5 to commence Bio Campus II capacity expansion
News Brief Samsung Biologics recognized for business excellence in receiving the 2023 CDMO Leadership Awards for 10th consecutive year
Samsung BIO Insight Samsung Biologics continues to expand for sustainable future
Samsung Biologics recently opened a regional office in New Jersey to extend its client support in the U.S. and beyond. Along with the company’s R&D Center in San Francisco, Samsung Biologics expects the new office to streamline communication and enable the company to work in closer proximity to clients based in the U.S. and Europe.
|
Kyung-Sik Choi (Right), President and CEO of Samsung Electronics North America, attends the opening ceremony to welcome Samsung Biologics employees to New Jersey |
“The opening of our new sales office is a significant moment for us as we further seek to strengthen our global relationships with both existing and new clients in the U.S. and Europe,” said John Rim, President and CEO of Samsung Biologics, during the opening ceremony. “This reflects our dedication to continuously anticipate and meet the needs of our clients, wherever they are located.”
Samsung Biologics says the increased U.S. presence will enable the company to provide support for clients with even greater agility and flexibility, as well as engage the broader biotech industry more than ever.
“Our employees lead with a client satisfaction mindset, and thanks to their commitment and drive, this location will enable us to develop stronger relationships and better tailor solutions for our clients,” said Kevin Sharp, Vice President and Head of Samsung Biologics America Sales.
|
Samsung Biologics’ New Jersey office receives warm welcome from the Samsung Electronics North America team |
In addition to its U.S. footprint, the company will expand its headquarters in Korea with the construction of a fifth plant as part of its second Bio Campus. In response to increased global demand for biopharmaceutical products, Samsung Biologics will invest KRW 7.5 trillion to fulfill the company’s strategic commitment to continuous capacity expansion at its Songdo headquarters.
The company also plans to diversify its portfolio to include next generation biomedicines, including bispecific antibodies and antibody drug conjugates. Samsung Biologics will continue to provide customers with even greater innovation and services that will increase speed to market and boost patient access to live-saving treatments.
Related contents
Press Release Samsung Biologics announces construction of Plant 5 to commence Bio Campus II capacity expansion
News Brief Samsung Biologics recognized for business excellence in receiving the 2023 CDMO Leadership Awards for 10th consecutive year
Samsung BIO Insight Samsung Biologics continues to expand for sustainable future